Literature DB >> 8625522

Distribution of activated complement, C3b, and its degraded fragments, iC3b/C3dg, in the colonic mucosa of ulcerative colitis (UC).

T Ueki1, M Mizuno, T Uesu, T Kiso, J Nasu, T Inaba, Y Kihara, Y Matsuoka, H Okada, T Fujita, T Tsuji.   

Abstract

The third component of complement (C3) is central to both the classical and alternative pathways in complement activation. In this study, involvement of C3 activation in the mucosal injury of UC was investigated. We examined the distribution of activated (C3b) and degraded fragments (iC3b/C3dg) of C3, terminal complement complex (TCC), and complement regulatory proteins in normal and diseased colonic mucosa including UC and other types of colitis using immunohistochemical techniques at the level of light and electron microscopy. While C3b and iC3b/C3dg staining was negligible in the normal mucosa, iC3b/C3dg and, to a lesser extent, C3b were deposited in UC mucosa along the epithelial basement membrane. The deposition was enhanced in relation to the severity of mucosal inflammation (C3b, P less than 0.05; iC3b/C3dg, P less than 0.01). Epithelial deposition of TCC was not observed in most UC mucosa. Immunoelectron microscopy showed that C3b and iC3b/C3dg were distributed mainly along the epithelial basement membrane and the underlying connective tissue in a granular, studded manner, and weakly present along the basolateral surface of epithelial cells. These C3 fragments were also deposited in inflammatory control mucosa such as ischaemic and infectious colitis. Our findings suggest that deposition of the C3 fragments occurs in inflamed colonic mucosa of diverse etiologies, including UC, but to define a role of the deposition in the development of mucosal injury in UC awaits direct study.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8625522      PMCID: PMC2200416          DOI: 10.1046/j.1365-2249.1996.17721.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  14 in total

1.  Expression of cell membrane complement regulatory glycoproteins along the normal and diseased human gastrointestinal tract.

Authors:  A E Berstad; P Brandtzaeg
Journal:  Gut       Date:  1998-04       Impact factor: 23.059

Review 2.  Immunopathology of human inflammatory bowel disease.

Authors:  P Brandtzaeg; G Haraldsen; J Rugtveit
Journal:  Springer Semin Immunopathol       Date:  1997

3.  Cytokine-stimulated release of decay-accelerating factor (DAF;CD55) from HT-29 human intestinal epithelial cells.

Authors:  J Nasu; M Mizuno; T Uesu; K Takeuchi; T Inaba; S Ohya; M Kawada; K Shimo; H Okada; T Fujita; T Tsuji
Journal:  Clin Exp Immunol       Date:  1998-09       Impact factor: 4.330

4.  High-Fat Diet-Induced Complement Activation Mediates Intestinal Inflammation and Neoplasia, Independent of Obesity.

Authors:  Stephanie K Doerner; Edimara S Reis; Elaine S Leung; Justine S Ko; Jason D Heaney; Nathan A Berger; John D Lambris; Joseph H Nadeau
Journal:  Mol Cancer Res       Date:  2016-08-17       Impact factor: 5.852

5.  Regulation of the alternative pathway of complement modulates injury and immunity in a chronic model of dextran sulphate sodium-induced colitis.

Authors:  M Elvington; J Schepp-Berglind; S Tomlinson
Journal:  Clin Exp Immunol       Date:  2015-03       Impact factor: 4.330

6.  CD46-induced immunomodulatory CD4+ T cells express the adhesion molecule and chemokine receptor pattern of intestinal T cells.

Authors:  Shannon K Alford; Gregory D Longmore; William F Stenson; Claudia Kemper
Journal:  J Immunol       Date:  2008-08-15       Impact factor: 5.422

7.  High normal serum levels of C3 and C1 inhibitor, two acute-phase proteins belonging to the complement system, occur more frequently in patients with Crohn's disease than ulcerative colitis.

Authors:  László Bene; George Füst; Béla Fekete; Agota Kovács; Laura Horváth; Zoltán Prohászka; Kata Miklós; Gábor Pálos; Mohamed Daha; Henriette Farkas; Lilian Varga
Journal:  Dig Dis Sci       Date:  2003-06       Impact factor: 3.199

8.  A novel protocol allowing oral delivery of a protein complement inhibitor that subsequently targets to inflamed colon mucosa and ameliorates murine colitis.

Authors:  M Elvington; P Blichmann; F Qiao; M Scheiber; C Wadsworth; I Luzinov; J Lucero; A Vertegel; S Tomlinson
Journal:  Clin Exp Immunol       Date:  2014-08       Impact factor: 4.330

9.  Complement-dependent injury and protection in a murine model of acute dextran sulfate sodium-induced colitis.

Authors:  Jennifer Schepp-Berglind; Carl Atkinson; Michelle Elvington; Fei Qiao; Peter Mannon; Stephen Tomlinson
Journal:  J Immunol       Date:  2012-05-07       Impact factor: 5.422

10.  Management of Shiga toxin-associated Escherichia coli-induced haemolytic uraemic syndrome: randomized clinical trials are needed.

Authors:  Diana Karpman
Journal:  Nephrol Dial Transplant       Date:  2012-10       Impact factor: 5.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.